For research use only. Not for therapeutic Use.
OPC-167832（Cat No.:I033913）is a novel anti-tuberculosis agent under investigation for its efficacy against Mycobacterium tuberculosis, including multi-drug-resistant (MDR) and extensively drug-resistant (XDR) strains. Developed by Otsuka Pharmaceutical, OPC-167832 targets the enzyme DprE1, essential for bacterial cell wall synthesis, leading to bacterial cell death. This compound has demonstrated potent activity in preclinical studies, with the potential to shorten tuberculosis treatment durations and enhance outcomes in resistant cases. Its selectivity and mechanism make it a promising candidate in the development of new, effective TB treatment regimens.
| Catalog Number | I033913 |
| CAS Number | 1883747-71-4 |
| Synonyms | OPC-167832; OPC 167832; OPC167832; |
| Molecular Formula | C21H20ClF3N2O4 |
| Purity | 98% |
| Target | Bacterial |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy]-8-fluoro-3,4-dihydro-1H-quinolin-2-one |
| InChI | InChI=1S/C21H20ClF3N2O4/c22-11-7-14(24)20(15(25)8-11)27-6-5-21(30,17(28)9-27)10-31-16-3-2-13(23)19-12(16)1-4-18(29)26-19/h2-3,7-8,17,28,30H,1,4-6,9-10H2,(H,26,29)/t17-,21-/m1/s1 |
| InChIKey | XZISSTDXPBUCJA-DYESRHJHSA-N |
| SMILES | C1CC(=O)NC2=C(C=CC(=C21)OC[C@@]3(CCN(C[C@H]3O)C4=C(C=C(C=C4F)Cl)F)O)F |
| Reference | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832989/#!po=9.48276 |
